Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2392
{ "count": 24455, "next": "http://api.gregory-ms.com/articles/?format=api&page=2393", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2391", "results": [ { "article_id": 549, "title": "The Role of Natural Killer Cells in Autoimmune Diseases", "summary": "<div><p>Front Immunol. 2021 Feb 25;12:622306. doi: 10.3389/fimmu.2021.622306. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Natural killer (NK) cells, the large granular lymphocytes differentiated from the common lymphoid progenitors, were discovered in early 1970's. They are members of innate immunity and were initially defined by their strong cytotoxicity against virus-infected cells and by their important effector functions in anti-tumoral immune responses. Nowadays, NK cells are classified among the recently discovered innate lymphoid cell subsets and have capacity to influence both innate and adaptive immune responses. Therefore, they can be considered as innate immune cells that stands between the innate and adaptive arms of immunity. NK cells don't express T or B cell receptors and are recognized by absence of CD3. There are two major subgroups of NK cells according to their differential expression of CD16 and CD56. While CD16<sup>+</sup>CD56<sup>dim</sup> subset is best-known by their cytotoxic functions, CD16<sup>-</sup>CD56<sup>bright</sup> NK cell subset produces a bunch of cytokines comparable to CD4<sup>+</sup> T helper cell subsets. Another subset of NK cells with production of interleukin (IL)-10 was named as NK regulatory cells, which has suppressive properties and could take part in immune-regulatory responses. Activation of NK cells is determined by a delicate balance of cell-surface receptors that have either activating or inhibitory properties. On the other hand, a variety of cytokines including IL-2, IL-12, IL-15, and IL-18 influence NK cell activity. NK-derived cytokines and their cytotoxic functions through induction of apoptosis take part in regulation of the immune responses and could contribute to the pathogenesis of many immune mediated diseases including ankylosing spondylitis, Behçet's disease, multiple sclerosis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus and type-1 diabetes. Dysregulation of NK cells in autoimmune disorders may occur through multiple mechanisms. Thanks to the rapid developments in biotechnology, progressive research in immunology enables better characterization of cells and their delicate roles in the complex network of immunity. As NK cells stand in between innate and adaptive arms of immunity and \"bridge\" them, their contribution in inflammation and immune regulation deserves intense investigations. Better understanding of NK-cell biology and their contribution in both exacerbation and regulation of inflammatory disorders is a requisite for possible utilization of these multi-faceted cells in novel therapeutic interventions.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33717125/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33717125</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7947192/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7947192</a> | DOI:<a href=\"https://doi.org/10.3389/fimmu.2021.622306\">10.3389/fimmu.2021.622306</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33717125/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-25T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Immunology", "authors": [ { "author_id": 244364, "given_name": "Umut Can", "family_name": "Kucuksezer", "ORCID": null, "country": null }, { "author_id": 244365, "given_name": "Esin", "family_name": "Aktas Cetin", "ORCID": null, "country": null }, { "author_id": 244366, "given_name": "Fehim", "family_name": "Esen", "ORCID": null, "country": null }, { "author_id": 244367, "given_name": "Ilhan", "family_name": "Tahrali", "ORCID": null, "country": null }, { "author_id": 244368, "given_name": "Nilgun", "family_name": "Akdeniz", "ORCID": null, "country": null }, { "author_id": 244369, "given_name": "Metin Yusuf", "family_name": "Gelmez", "ORCID": null, "country": null }, { "author_id": 244370, "given_name": "Gunnur", "family_name": "Deniz", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "The Role", "Natural Killer Cells", "Autoimmune Diseases" ], "doi": "10.3389/fimmu.2021.622306", "access": "open", "takeaways": " Natural killer (NK) cells stand in between innate and adaptive arms of immunity and \"bridge\" them . NK cells don't express T or B cell receptors and are recognized by absence of CD3 . NK-derived cytokines and their cytotoxic functions through induction of apoptosis take part in regulation of the immune responses .", "categories": [] }, { "article_id": 545, "title": "Oxidative Stress and Vitamin D as Predictors in Multiple Sclerosis", "summary": "<div><p>Curr Health Sci J. 2020 Oct-Dec;46(4):371-378. doi: 10.12865/CHSJ.46.04.07. Epub 2020 Dec 31.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Multiple Sclerosis (MS) is a multifactorial demyelinating diseases that affect mostly the young and active people. Here, is crucial to identify new strategies in order to slow down the diseases progression and maintain a good functional outcome. Our hypothesis was that the interconnection between anti-oxidant molecules and anti-inflammatory or neuroprotective molecules can act as predictors of diseases progression. In the study were included 36 patients with MS. Inclusion criteria were the following: patients over 18 years old were divided in three groups, 16 relapsing-remitting MS (RRMS) group, 10 secondary progressive MS (SPMS) group and 10 healthy control group. We showed that the vitamin D sufficiency did not improve de EDSS score in the later stage of diseases. Also, we showed that in the early stage (RRMS) the vitamin D status can significantly improve the EDSS and IADL score and may slow down the diseases progression. started with the early stage of diseases (RRMS) we found that catalase activity, an enzyme that act as anti-oxidant, is significantly decreased compare with healthy people, and can be associated with a low level of vitamin D. we concluded that a pro-oxidative and anti-oxidative balance is an important player in the multifactorial mechanism of MS diseases progression and additional prospective studies are needed to determine optimal vitamin D levels that lead to clinical and immunological benefits for patients with MS. Long-term follow-up studies using high-dose vitamin D supplementation are needed to confirm the preliminary results of the studies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33717511/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33717511</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7948027/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7948027</a> | DOI:<a href=\"https://doi.org/10.12865/CHSJ.46.04.07\">10.12865/CHSJ.46.04.07</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33717511/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-01-01T00:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Oxidative Stress", "Vitamin D", "Predictors", "Multiple Sclerosis" ], "doi": "10.12865/CHSJ.46.04.07", "access": "restricted", "takeaways": " Multiple Sclerosis is a multifactorial demyelinating diseases that affect mostly the young and active people . The interconnection between anti-oxidant molecules and anti-inflammatory or neuroprotective molecules can act as predictors of diseases progression . Long-term follow-up studies using high-dose vitamin D supplementation are needed .", "categories": [] }, { "article_id": 551, "title": "Animal modeling of lower urinary tract dysfunction associated with multiple sclerosis: Part I: Justification of the mouse model for MS research", "summary": "<div><p>Neurourol Urodyn. 2021 Mar 14. doi: 10.1002/nau.24649. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Lower urinary tract symptoms and dysfunction (LUTS/LUTD) contribute to loss of quality of life, morbidity, and need for medical intervention in most patients with multiple sclerosis (MS). Although MS is an inflammatory neurodegenerative disease, clinical manifestations including continence control disorders have traditionally been attributed to the loss of neural signaling due to neurodegeneration. Clinical approaches to MS-LUTS/LUTD have focused on addressing symptoms in the context of urodynamic dysfunctions as pathophysiologic understandings are incomplete. The mouse model provides a useful research platform for the discovery of more detailed molecular, cellular, and tissue-level knowledge of the disease and its clinical manifestations. The aim of this two-part review is to provide a state-of-the-art update on the use of the mouse model for MS research, with a focus on lower urinary tract symptoms. Part I presents a summary of the current understanding of MS pathophysiology, the impact on lower urinary tract symptoms, and briefly introduces the types of mouse models available to study MS. Part II presents the common animal models that are currently available to study MS, their mechanism, relevance to MS-LUTS/LUTD and their urinary pathophysiology, advantages, and disadvantages.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33719097/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33719097</a> | DOI:<a href=\"https://doi.org/10.1002/nau.24649\">10.1002/nau.24649</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33719097/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "source": "PubMed", "publisher": "Wiley", "container_title": "Neurourology and Urodynamics", "authors": [ { "author_id": 198777, "given_name": "Ramalakshmi", "family_name": "Ramasamy", "ORCID": "http://orcid.org/0000-0003-4067-0511", "country": "US" }, { "author_id": 198778, "given_name": "Phillip P.", "family_name": "Smith", "ORCID": "http://orcid.org/0000-0003-0160-8387", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Animal modeling", "lower urinary tract dysfunction", "multiple sclerosis", "Part I", "Justification", "the mouse model", "MS research" ], "doi": "10.1002/nau.24649", "access": "open", "takeaways": " Lower urinary tract symptoms and dysfunction contribute to loss of quality of life, morbidity, and need for medical intervention in most patients with multiple sclerosis . MS is an inflammatory neurodegenerative disease, clinical manifestations including continence control disorders have traditionally been attributed to the loss of neural signaling . The aim of this two-part review is to provide a state-of-the-art update on the use of the mouse model .", "categories": [] }, { "article_id": 550, "title": "Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT() Autoinjector: A Prospective Observational Cohort Study", "summary": "<div><p>Front Neurol. 2021 Feb 24;12:643126. doi: 10.3389/fneur.2021.643126. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> In patients with multiple sclerosis (MS), non-adherence to disease-modifying drug therapy is associated with an increased rate of MS relapses. Early identification of patients at risk of non-adherence would allow provision of timely and individualized support. The aim of the BETAPREDICT study was to investigate potential predictors of adherence in patients with MS in Germany treated with interferon β-1b (IFNβ-1b) using the BETACONNECT® autoinjector. <b>Methods:</b> BETAPREDICT was a national, multi-center, prospective, non-interventional, single-arm, 24-month cohort study of patients with relapsing-remitting MS or clinically isolated syndrome receiving IFNβ-1b via the BETACONNECT® autoinjector (ClinicalTrials.gov: NCT02486640). Injection data were captured by the autoinjector. The primary objective was to determine baseline predictors of compliance, persistence, and adherence to IFNβ-1b treatment after 12- and 24 months using multivariable-adjusted regression. Secondary objectives included evaluation of satisfaction with the autoinjector, injection site pain, vitamin and nutrient supplementation, clinical course, and patient-related outcome measures. <b>Results:</b> Of 165 patients enrolled, 153 were available for analysis (120 with autoinjector data). Seventy-two patients left the study prematurely. Compliance (<i>N</i> = 120), persistence (<i>N</i> = 153), and adherence (<i>N</i> = 120) at 24 months were 89.1, 53.6, and 41.7%, respectively. Compliance at 12- and 24 months was predicted by intake of vitamin D supplements and absence of specific injection site reactions. Positive predictors of persistence included age (at 12- and 24 months) and previous duration of treatment (at 12 months), while intake of vitamins/nutrients other than vitamin D was a negative predictor (at 12 months). Positive predictors of adherence at 24 months were age and being experienced with IFNβ-1b. Higher scores in specific SF-36 subscales were positive predictors of medication-taking behavior at 24 months. Satisfaction with the autoinjector was high at baseline and 24 months (median score: 9 out of 10). <b>Conclusions:</b> Compliance with IFNβ-1b treatment among participants still under observation remained high over a 24-month period, while persistence and adherence continuously declined. Multiple factors affected medication-taking behavior, including patient characteristics, treatment history, injection site reactions, patients' perception of their health and support programs. The importance of these factors may differ among patients according to their individual situation.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33716945/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33716945</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7943887/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7943887</a> | DOI:<a href=\"https://doi.org/10.3389/fneur.2021.643126\">10.3389/fneur.2021.643126</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33716945/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-24T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 244372, "given_name": "Wolfgang", "family_name": "Köhler", "ORCID": null, "country": null }, { "author_id": 158672, "given_name": "Kirsten", "family_name": "Bayer-Gersmann", "ORCID": "http://orcid.org/0000-0003-1449-8519", "country": null }, { "author_id": 244373, "given_name": "Thomas", "family_name": "Neußer", "ORCID": null, "country": null }, { "author_id": 158674, "given_name": "Markus", "family_name": "Schürks", "ORCID": "http://orcid.org/0000-0002-0477-8288", "country": null }, { "author_id": 153754, "given_name": "Tjalf", "family_name": "Ziemssen", "ORCID": "http://orcid.org/0000-0001-8799-8202", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Predictors", "Adherence", "Patients", "Multiple Sclerosis", "the BETACONNECT() Autoinjector", "A Prospective Observational Cohort Study" ], "doi": "10.3389/fneur.2021.643126", "access": "open", "takeaways": " Non-adherence to disease-modifying drug therapy is associated with an increased rate of MS relapses . The aim of the BETAPREDICT study was to investigate potential predictors of adherence in patients with MS in Germany treated with interferon β-1b . Compliance at 12- and 24 months predicted by intake of vitamin D supplements and absence of specific injection site reactions .", "categories": [] }, { "article_id": 547, "title": "Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study", "summary": "<div><p>Mult Scler J Exp Transl Clin. 2021 Feb 24;7(1):2055217321990852. doi: 10.1177/2055217321990852. eCollection 2021 Jan-Mar.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: In the Phase 3, 96-week ORACLE-MS study, cladribine tablets 10 mg (3.5 or 5.25 mg/kg cumulative dosage over two years) significantly reduced lesions associated with multiple sclerosis versus placebo in participants following a first clinical demyelinating event (FCDE).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To determine the timing of effects of cladribine tablets on lesion activity assessed by magnetic resonance imaging (MRI).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: This <i>post hoc</i> analysis assessed the effect of cladribine tablets versus placebo in ORACLE-MS on secondary MRI endpoints including T1 gadolinium-enhancing (Gd+), new or enlarging T2 lesions, and combined unique active lesions assessed on MRI scans performed at screening and every 3 months thereafter.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Compared to placebo, cladribine tablets 3.5 mg/kg treatment appeared to lead to a trend of reductions in the mean number of T1 Gd+ lesions by Week 13 (first post-baseline scan: 0.37 vs. 1.00), new or enlarging T2 (0.20 vs. 1.01) and combined unique active (0.29 vs. 1.91) lesions by Week 24. Low lesion counts were maintained with cladribine tablets throughout 96 weeks. Similar results were observed with the 5.25 mg/kg dosage.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In participants with an FCDE, cladribine tablets appeared to reduce lesion numbers within 13 weeks (time of first evaluation).</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33717501/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33717501</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7925953/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7925953</a> | DOI:<a href=\"https://doi.org/10.1177/2055217321990852\">10.1177/2055217321990852</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33717501/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-24T00:00:00Z", "source": "PubMed", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal - Experimental, Translational and Clinical", "authors": [ { "author_id": 153178, "given_name": "Mark S", "family_name": "Freedman", "ORCID": "http://orcid.org/0000-0003-1255-9701", "country": "CA" }, { "author_id": 244379, "given_name": "Patricia K", "family_name": "Coyle", "ORCID": null, "country": null }, { "author_id": 149342, "given_name": "Giancarlo", "family_name": "Comi", "ORCID": "http://orcid.org/0000-0002-6989-1054", "country": null }, { "author_id": 244380, "given_name": "Susan", "family_name": "L Scarberry", "ORCID": null, "country": null }, { "author_id": 175244, "given_name": "Doris", "family_name": "Damian", "ORCID": "http://orcid.org/0000-0002-9562-9746", "country": null }, { "author_id": 244381, "given_name": "Yann", "family_name": "Hyvert", "ORCID": null, "country": null }, { "author_id": 208598, "given_name": "Fernando", "family_name": "Dangond", "ORCID": "http://orcid.org/0000-0002-6723-4229", "country": null }, { "author_id": 242172, "given_name": "Andrew", "family_name": "Galazka", "ORCID": null, "country": null }, { "author_id": 208600, "given_name": "Dominic", "family_name": "Jack", "ORCID": "http://orcid.org/0000-0001-8629-553X", "country": null }, { "author_id": 244382, "given_name": "Lori A", "family_name": "Lebson", "ORCID": null, "country": null }, { "author_id": 244383, "given_name": "Thomas P", "family_name": "Leist", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Early MRI outcomes", "participants", "a first clinical demyelinating event", "risk", "multiple sclerosis", "the ORACLE-MS study" ], "doi": "10.1177/2055217321990852", "access": "open", "takeaways": " Cladribine tablets 10 mg (3.5 or 5.25 mg/kg cumulative dosage over two years) significantly reduced lesions associated with multiple sclerosis .", "categories": [] }, { "article_id": 546, "title": "Effectiveness of film as a health communication tool to improve perceptions and attitudes in multiple sclerosis", "summary": "<div><p>Mult Scler J Exp Transl Clin. 2021 Feb 27;7(1):2055217321995947. doi: 10.1177/2055217321995947. eCollection 2021 Jan-Mar.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Health communication tools like film are capable of reducing health disparities and could be effective in addressing negative illness perceptions of MS in Hispanics/Latinx.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To test the feasibility of using a culturally appropriate short narrative film to examine illness perceptions overtime and attitudes in Hispanics/Latinx affected with MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Participants were assigned to view a short narrative film (n = 130) or not (n = 106). The Brief Illness Perception Questionnaire (BIPQ) was used to examine illness perceptions at baseline, one and three months. Focus groups were conducted at 6 months. Measures of sociocultural integration were obtained. Individual group BIPQ domains were evaluated over time using paired sample t-test. Multivariate linear regression was used to examine predictors of BIPQ change.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: A more positive perception of <i>treatment</i> (p < 0.0001) and <i>understanding</i> (p = 0.0003) were seen at 3 months for those exposed to film. Focus groups were effective in highlighting that the perceived disease prognosis, family support and awareness of MS contributes to attitudes. Exposure to film was found to be the strongest predictor (Beta:6.31, p = 0.01) of BIPQ change at three months.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Our results provide support that a short narrative film of MS in Hispanics/Latinx is a feasible intervention to change perceptions of MS to a more positive view.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33717502/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33717502</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7923991/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7923991</a> | DOI:<a href=\"https://doi.org/10.1177/2055217321995947\">10.1177/2055217321995947</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33717502/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-27T00:00:00Z", "source": "PubMed", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal - Experimental, Translational and Clinical", "authors": [ { "author_id": 192257, "given_name": "Horacio", "family_name": "Chiong-Rivero", "ORCID": "http://orcid.org/0000-0001-5233-7754", "country": null }, { "author_id": 244347, "given_name": "Michael", "family_name": "Robers", "ORCID": null, "country": null }, { "author_id": 244348, "given_name": "Andrea", "family_name": "Martinez", "ORCID": null, "country": null }, { "author_id": 244349, "given_name": "Clara P", "family_name": "Manrique", "ORCID": null, "country": null }, { "author_id": 244350, "given_name": "Astrid", "family_name": "Diaz", "ORCID": null, "country": null }, { "author_id": 244351, "given_name": "Kelly", "family_name": "Polito", "ORCID": null, "country": null }, { "author_id": 244353, "given_name": "Borna", "family_name": "Vajdi", "ORCID": null, "country": null }, { "author_id": 244355, "given_name": "Chan", "family_name": "Chan", "ORCID": null, "country": null }, { "author_id": 244357, "given_name": "Margaret", "family_name": "Burnett", "ORCID": null, "country": null }, { "author_id": 244360, "given_name": "Silvia R", "family_name": "Delgado", "ORCID": null, "country": null }, { "author_id": 244362, "given_name": "Angel", "family_name": "Chinea", "ORCID": null, "country": null }, { "author_id": 170040, "given_name": "Jacob L.", "family_name": "McCauley", "ORCID": "http://orcid.org/0000-0002-1805-1733", "country": "US" }, { "author_id": 153308, "given_name": "L", "family_name": "Amezcua", "ORCID": "http://orcid.org/0000-0003-1542-7819", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Effectiveness", "film", "a health communication tool", "perceptions", "attitudes", "multiple sclerosis" ], "doi": "10.1177/2055217321995947", "access": "open", "takeaways": " Short narrative film could be effective in addressing negative illness perceptions of MS in Hispanics/Latinx . Exposure to film was found to be the strongest predictor of BIPQ change at three months .", "categories": [] }, { "article_id": 552, "title": "Differential Gene Expression Patterns in Blood and Cerebrospinal Fluid of Multiple Sclerosis and Neuro-Behcet Disease", "summary": "<div><p>Front Genet. 2021 Feb 26;12:638236. doi: 10.3389/fgene.2021.638236. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Inflammatory demyelinating disorders of the central nervous system are debilitating conditions of the young adult, here we focus on multiple sclerosis (MS) and neuro-Behçet disease (NBD). MS is an autoimmune disorder of the central nervous system. NBD, a neurological manifestation of an idiopathic chronic relapsing multisystem inflammatory disease, the behçet disease. The diagnosis of MS and NBD relies on clinical symptoms, magnetic resonance imaging and laboratory tests. At first onset, clinical and imaging similarities between the two disorders may occur, making differential diagnosis challenging and delaying appropriate management. Aiming to identify additional discriminating biomarker patterns, we measured and compared gene expression of a broad panel of selected genes in blood and cerebrospinal fluid (CSF) cells of patients suffering from NBD, MS and non inflammatory neurological disorders (NIND). To reach this aim, bivariate and multivariate analysis were applied. The Principal Analysis Component (PCA) highlighted distinct profiles between NBD, MS, and controls. Transcription factors foxp3 in the blood along with IL-4, IL-10, and IL-17 expressions were the parameters that are the main contributor to the segregation between MS and NBD clustering. Moreover, parameters related to cellular activation and inflammatory cytokines within the CSF clearly differentiate between the two inflammatory diseases and the controls. We proceeded to ROC analysis in order to identify the most distinctive parameters between both inflammatory neurological disorders. The latter analysis suggested that IL-17, CD73 in the blood as well as IL-1β and IL-10 in the CSF were the most discriminating parameters between MS and NBD. We conclude that combined multi-dimensional analysis in blood and CSF suggests distinct mechanisms governing the pathophysiology of these two neuro-inflammatory disorders.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33719347/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33719347</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7954360/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">PMC7954360</a> | DOI:<a href=\"https://doi.org/10.3389/fgene.2021.638236\">10.3389/fgene.2021.638236</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33719347/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-26T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Genetics", "authors": [ { "author_id": 173726, "given_name": "Olfa", "family_name": "Maghrebi", "ORCID": "http://orcid.org/0000-0002-8824-6659", "country": null }, { "author_id": 244415, "given_name": "Mariem", "family_name": "Hanachi", "ORCID": null, "country": null }, { "author_id": 244416, "given_name": "Khadija", "family_name": "Bahrini", "ORCID": null, "country": null }, { "author_id": 244417, "given_name": "Mariem", "family_name": "Kchaou", "ORCID": null, "country": null }, { "author_id": 244418, "given_name": "Cyrine", "family_name": "Jeridi", "ORCID": null, "country": null }, { "author_id": 244419, "given_name": "Samir", "family_name": "Belal", "ORCID": null, "country": null }, { "author_id": 244420, "given_name": "Samia", "family_name": "Ben Sassi", "ORCID": null, "country": null }, { "author_id": 244421, "given_name": "Mohamed-Ridha", "family_name": "Barbouche", "ORCID": null, "country": null }, { "author_id": 244422, "given_name": "Oussama", "family_name": "Souiai", "ORCID": null, "country": null }, { "author_id": 244423, "given_name": "Meriam", "family_name": "Belghith", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "Differential Gene Expression Patterns", "Blood", "Cerebrospinal Fluid", "Multiple Sclerosis", "Neuro-Behcet Disease" ], "doi": "10.3389/fgene.2021.638236", "access": "open", "takeaways": " Multiple sclerosis (MS) and neuro-Behçet disease (NBD) are debilitating conditions of the young adult . MS is an autoimmune disorder of the central nervous system . NBD is a neurological manifestation of an idiopathic chronic relapsing multisystem inflammatory disease . MS and NBD rely on clinical symptoms, magnetic resonance imaging and laboratory tests .", "categories": [] }, { "article_id": 544, "title": "There is an impairment in time perception of patients with multiple sclerosis", "summary": "<div><p>Somatosens Mot Res. 2021 Mar 9:1-6. doi: 10.1080/08990220.2021.1879777. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: The objective of this study is to examine time perception impairment in multiple sclerosis (MS) patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHOD: The study was performed with 60 MS patients and 60 age-matched healthy people. Estimation and Production Tests were carried out with a standard personal laptop computer and participants were aware to count the seconds by the 'start' command and to stop by the 'stop' command. The outcome measure was the ratio between the estimated duration and the target (7 s, 32 s, or 58 s) one for the Estimation Test and the Produced duration and the target (7 s, 32 s, or 58 s) one for the Production Test; and each time duration was repeated three times both for Production and Estimation Tests.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: We found a significant difference in the Estimation Test (7 s, 32 s, 58 s), and the Production Test (7 s, 32 s, 58 s) between the MS group and healthy control group (<i>p</i> < .05). It was observed that patients with MS had a higher deviation from the target time compared to the control group. It was found that this difference was statistically significant (<i>p</i> < .05). There was a high and negative correlation between the Estimation and Production Tests in MS patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: In conclusion, our data suggests that time estimation and production are disturbed in MS patients, and cognitive rehabilitation is required for most of them.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33719839/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210315155920&v=2.14.3\">33719839</a> | DOI:<a href=\"https://doi.org/10.1080/08990220.2021.1879777\">10.1080/08990220.2021.1879777</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33719839/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "source": "PubMed", "publisher": "Informa UK Limited", "container_title": "Somatosensory & Motor Research", "authors": [ { "author_id": 204653, "given_name": "Esra", "family_name": "Dogru-Huzmeli", "ORCID": "http://orcid.org/0000-0002-7025-8192", "country": "TR" }, { "author_id": 267923, "given_name": "Taskin", "family_name": "Duman", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T19:59:22Z", "noun_phrases": [ "an impairment", "time", "perception", "patients", "multiple sclerosis" ], "doi": "10.1080/08990220.2021.1879777", "access": "restricted", "takeaways": " Somatosens Mot Res. Res. 2021 Mar 9:1-6.01-6 . MS patients with MS had a higher deviation from the target time .", "categories": [] }, { "article_id": 543, "title": "Post-COVID-19 encephalomyelitis", "summary": "AbstractSince the outbreak of coronavirus disease 2019 (COVID-19), a growing number of cases of acute transverse myelitis associated with COVID-19 have been reported. Here, we present the case of a patient who developed sensory ataxia after COVID-19 with MR lesions suggestive for longitudinal myelitis and in the splenium of the corpus callosum. The patient was successfully treated with immunoadsorption.", "link": "https://neurolrespract.biomedcentral.com/articles/10.1186/s42466-021-00113-4", "published_date": "2021-03-15T00:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Research and Practice", "authors": [ { "author_id": 160277, "given_name": "Ji-Won", "family_name": "Kim", "ORCID": "http://orcid.org/0000-0002-3903-3956", "country": null }, { "author_id": 244323, "given_name": "Nuran", "family_name": "Abdullayev", "ORCID": null, "country": null }, { "author_id": 244324, "given_name": "Janina", "family_name": "Neuneier", "ORCID": null, "country": null }, { "author_id": 212884, "given_name": "Gereon R.", "family_name": "Fink", "ORCID": "http://orcid.org/0000-0002-8230-1856", "country": null }, { "author_id": 208237, "given_name": "Helmar C.", "family_name": "Lehmann", "ORCID": "http://orcid.org/0000-0001-6205-2293", "country": "DE" } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T16:59:51Z", "noun_phrases": [ "Post-COVID-19 encephalomyelitis" ], "doi": "10.1186/s42466-021-00113-4", "access": "open", "takeaways": " A patient developed sensory ataxia after COVID-19 with MR lesions suggestive for longitudinal myelitis and in the splenium", "categories": [] }, { "article_id": 542, "title": "Correlation of osteoarthritis or rheumatoid arthritis with bone mineral density in adults aged 20–59 years", "summary": "Background: It is reported that osteoporosis commonly occurs among patients with rheumatoid arthritis (RA), whereas the association between osteoporosis and osteoarthritis (OA) remains controversial. Our aim in this study was to investigate the association between BMD, as a marker of osteoporosis, and OA and RA among adults 20−59 years of age, using a population-based sample from the National Health and Nutrition Examination Survey (NHANES).MethodsOur analysis was based on the NHANES data collected between 2011 and 2018. Data regarding arthritis status and the type of arthritis (OA or RA) were obtained from questionnaires. Lumbar BMD was measured by dual-energy X-ray absorptiometry. The association between OA, RA, and lumbar BMD was evaluated using logistic regression models. Subgroup analyses, stratified by gender and race, were performed. The association between duration of arthritis and lumbar BMD was also investigated.ResultsA total of 11,094 adults were included in our study. Compared to the non-arthritis group, participants with OA had a higher lumbar BMD (β = 0.023, 95% CI 0.011–0.035), with no significant association between lumbar BMD and RA (β = 0.014, 95% CI − 0.003 to 0.031). On subgroup analyses stratified by gender, males with OA had a higher lumbar BMD compared to those without OA (β = 0.047, 95% CI 0.028–0.066). In females, OA was not associated with lumbar BMD (β = 0.007, 95% CI − 0.008 to 0.021). There was no association between lumbar BMD and RA in both males (β = 0.023, 95% CI − 0.003 to 0.048) and females (β = 0.008, 95% CI − 0.015 to 0.031). Duration of arthritis was not associated with lumbar BMD for both OA (β = − 0.0001, 95% CI − 0.0017 to 0.0015) and RA (β = 0.0006, 95% CI − 0.0012 to 0.0025).ConclusionsLumbar BMD was associated with OA but not with RA. While a higher lumbar BMD was associated with OA in males, but not in females. Our findings may improve our understanding between OA, RA, and bone health.", "link": "https://josr-online.biomedcentral.com/articles/10.1186/s13018-021-02338-0", "published_date": "2021-03-15T00:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "Journal of Orthopaedic Surgery and Research", "authors": [ { "author_id": 257527, "given_name": "Zhongxin", "family_name": "Zhu", "ORCID": null, "country": null }, { "author_id": 257528, "given_name": "Gangfeng", "family_name": "Hu", "ORCID": null, "country": null }, { "author_id": 257529, "given_name": "Fang", "family_name": "Jin", "ORCID": null, "country": null }, { "author_id": 215067, "given_name": "Xiaocong", "family_name": "Yao", "ORCID": "http://orcid.org/0000-0001-9491-7511", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-15T13:59:51Z", "noun_phrases": [ "Correlation", "osteoarthritis", "rheumatoid", "arthritis", "bone mineral density", "adults" ], "doi": "10.1186/s13018-021-02338-0", "access": "open", "takeaways": " Lumbar BMD, as a marker of osteoporosis, was measured by dual-energy X-ray absorptiometry . The association between OA, RA, and lumbar bMD was evaluated using logistic regression models . The study was based on data collected from the National Health and Nutrition Examination Survey (NHANES)", "categories": [] } ] }